DK2324013T6 - Broforbundne piperidinforbindelser af substitueret quinoxalintype og anvendelser deraf - Google Patents

Broforbundne piperidinforbindelser af substitueret quinoxalintype og anvendelser deraf Download PDF

Info

Publication number
DK2324013T6
DK2324013T6 DK09786064T DK09786064T DK2324013T6 DK 2324013 T6 DK2324013 T6 DK 2324013T6 DK 09786064 T DK09786064 T DK 09786064T DK 09786064 T DK09786064 T DK 09786064T DK 2324013 T6 DK2324013 T6 DK 2324013T6
Authority
DK
Denmark
Prior art keywords
compound
substituted
quinoxaline
type bridged
another embodiment
Prior art date
Application number
DK09786064T
Other languages
English (en)
Other versions
DK2324013T3 (da
Inventor
John W F Whitehead
Kouki Fuchino
Jiangchao Yao
Naoki Tsuno
Original Assignee
Purdue Pharma Lp
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41077776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2324013(T6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Purdue Pharma Lp, Shionogi & Co filed Critical Purdue Pharma Lp
Application granted granted Critical
Publication of DK2324013T3 publication Critical patent/DK2324013T3/da
Publication of DK2324013T6 publication Critical patent/DK2324013T6/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (28)

  1. P a t e n t k r a v j i— |_ i ^ IΛ Λ
    [Γλ ΛI /Μ\. eller et farmaceutisk acceptabelt derivat deraf, hvor: hver R2 er udvalgt uafhængigt fra -halogen; a er et helt tal udvalgt fra 0, 1 eller 2; b er et helt tal udvalgt fra 0 eller 1; hver R5 er udvalgt uafhængigt fra -H, -OH, -(Ci-C3)alkyl, -C(halogen)3 eller -halogen; Ri er -(C9-Ci4)cycloalkyl eller -(C9-Ci4)bicycloalkyl, der hver især er substitueret med 1,2 eller 3 uafhængigt valgte R3-grupper; hver R3 er udvalgt uafhængigt fra -(CrC4)alkyl, -(C2-C6)alkenyl, -(C2-C6)alkynyl eller -(C3-C6)cycloalkyl, og hvor det farmaceutisk acceptable derivat er udvalgt fra gruppen bestående af farmaceutisk acceptabelt salt, solvat, radiomærket forbindelse, stereoisomer, enantiomer, diastereomer, racemisk blanding og tautomer.
  2. 2. Forbindelse med Formel (I):
    (i) eller et farmaceutisk acceptabelt derivat deraf, hvor: hver R2 er udvalgt uafhængigt fra -halogen; a er et helt tal udvalgt fra 0, 1 eller 2; b er et helt tal udvalgt fra 0 eller 1; hver R5 er udvalgt uafhængigt fra -H, -OH, -(C-|-C3)alkyl, -C(halogen)3 eller -halogen; Ri er -(C9-Ci4)cycloalkyl eller -(C9-Ci4)bicycloalkyl; og hvert halogen udvalgt uafhængigt fra -F, -Cl, -Br eller -I, og hvor det farmaceutisk acceptable derivat er udvalgt fra gruppen bestående af farmaceutisk acceptabelt salt, solvat, radiomærket forbindelse, stereoisomer, enantiomer, diastereomer, racemisk blanding og tautomer, under den forudsætning, at forbindelsen ikke er O
    Γ\
  3. 3. Forbindelse ifølge krav 1 eller 2, hvor hver R5 er udvalgt uafhængigt fra -H, -(CrC3)alkyl, -C(halogen)3 eller -halogen.
  4. 4. Forbindelse ifølge et hvilket som helst af krav 1 til 3, hvor hver R5 er udvalgt uafhængigt fra -H, -CH3, -CF3 eller -F, og hver R5 fortrinsvis er -H.
  5. 5. Forbindelse ifølge et hvilket som helst af krav 1 til 4, hvor a er et helt tal udvalgt fra 0 eller 1 og fortrinsvis er 0.
  6. 6. Forbindelse ifølge et hvilket som helst af krav 1 til 5, hvor forbindelsen er en forbindelse med
    Formel (II): (II> eller et farmaceutisk acceptabelt derivat deraf, hvor det farmaceutisk acceptable derivat er udvalgt fra gruppen bestående af farmaceutisk acceptabelt salt, solvat, radiomærket forbindelse, stereoisomer, enantiomer, diastere-omer, racemisk blanding og tautomer.
  7. 7. Forbindelse ifølge et hvilket som helst af krav 1 til 6, hvor R2 er -F.
  8. 8. Forbindelse ifølge et hvilket som helst af krav 1 til 7, hvor 3-oxo-3,4-dihydroquinoxalin-2-carboxylsyre-delen af forbindelsen foreligger i endo- eller exo-konformation med hensyn til et broforbundne piperidins bro og fortrinsvis foreligger i endo-konformationen.
  9. 9. Forbindelse ifølge et hvilket som helst af krav 1 til 8, hvor Ri er -(C9-Ci2)cycloalkyl eller-(C9-Ci2)bicycloalkyl, og hvor fortrinsvis (i) Ri er -(C9-Ci2)bicycloalkyl, eller (ii) R-ι er -indanyl, -1,2,3,4-tetrahydronaphthalenyl, -5,6,7,8-tetrahydronaphthalenyl, -perhydronaphthalenyl, bicyclo[3.3.1]nonyl, bicy-clo[4.2.1]nonyl, bicyclo[3.3.2]decyl, bicyclo[4.2.2]decyl, bicyclo[4.3.1]decyl, bicyclo[3.3.3]undecyl, bicyclo[4.3.2]undecyl, eller bicyclo[4.3.3]dodecyl eller (iii) Ri er cycloundecyl.
  10. 10. Forbindelse ifølge et hvilket som helst af krav 1 til 9, hvor Ri is bicy-clo[3.3.1]nonyl, og Ri fortrinsvis er 2-bicyclo[3.3.1]nonyl, eller 3-bicyclo[3.3.1]nonyl.
  11. 11. Forbindelse ifølge et hvilket som helst af krav 1 til 10, hvor Ri foreligger i endo- eller exo-konformationen med hensyn til det broforbundne piperidins bro og fortrinsvis foreliggerer i exo-konformationen. i o PnrhinHoico jføige et hvilket som helst af krav 2 til 11, hvor Ri is:
  12. 13. Forbindelse ifølge et hvilket som helst af krav 1, 3-11, hvor der i en forbindelse med Formel (Γ) er 1,2 eller 3 R3-grupper, og hver R3 gruppe er udvalgt uafhængigt fra (i) -(CrC^alkyl, -(C2-C6)alkenyl og -(C2-C6)alkynyl; eller (ii) -(CrC^alkyl og -(C3-C6)cycloalkyl.
  13. 14. Forbindelse ifølge et hvilket som helst af krav 1, 3-11 eller 13, hvor i en forbindelse med Formel (Γ) hver R3-gruppe er methyl.
  14. 15. Forbindelse ifølge et hvilket som helst af krav 1, 3-11 eller 13-14, hvor der i en forbindelse med Formel (Γ) er én R3-gruppe til stede.
  15. 16. Forbindelse ifølge et hvilket som helst af krav 1, 3-11, 13 eller 15, hvor der i en forbindelse med Formel (Γ) er én R3-gruppe, der er (i) -(CrC^alkyl, -(C2-C6)alkenyl eller -(C2-C6)alkynyl; eller (ii) -(CrC^alkyl eller -(C3-C6)cycloalkyl.
  16. 17. Forbindelse ifølge et hvilket som helst af krav 1,3-11,13 eller 15-16, hvor der i en forbindelse med Formel (Γ) er én R3-gruppe, der er (i) -methyl, -ethyl, -n-propyl, -/sopropyl, -n-butyl, -sec-butyl, -/sobutyl, eller -tert-butyl eller (ii) -methyl, -ethyl, -/sopropyl, -/sobutyl eller-tert-butyl; og hvor R3 fortrinsvis er ethyl eller methyl.
  17. 18. Forbindelse ifølge et hvilket som helst af krav 1 til 17, hvor i en forbindelse med Formel (Γ) carbonatomet i Ri-gruppen, der er bundet til det broforbundne piperidins nitrogenatom, ikke er substitueret med en R3-gruppe.
  18. 19. Forbindelse ifølge et hvilket som helst af krav 1, 3-11, 13-16, 17, hvor option (i) og (ii) samt R3 er methyl, eller 18, hvor der i en forbindelse med Formel (Γ) Ri og R3 sammen er: jm λ/vi >λλλ- »λαλ-
    ^ ί nn mpst fortrinsvis er:
  19. 20. Forbindelse ifølge krav 1 med formlen:
    eller et farmaceutisk acceptabelt derivat deraf, hvor det farmaceutisk acceptable derivat er udvalgt fra gruppen bestående of farmaceutisk acceptabelt salt, solvat, radiomærket, stereoisomer, enantiomer, diastereomer, racemisk blanding og tautomer.
  20. 21. Forbindelse ifølge krav 2 med formlen:
    eller et farmaceutisk acceptabelt derivat deraf, hvor det farmaceutisk acceptable derivat er udvalgt fra gruppen bestående of farmaceutisk acceptabelt salt, solvat, radiomærket, stereoisomer, enantiomer, diastereomer, racemisk blanding og tautomer.
  21. 22. Forbindelse ifølge et hvilket som helst af krav 1 til 21, hvor det farmaceutisk acceptable derivat er a farmaceutisk acceptabelt salt, og fortrinsvis er et p-toluensulfonsyresalt, et sulfatsalt eller et phosphorsyresalt og fortrinsvis er et p-toluensulfonsyresalt.
  22. 23. Sammensætning, der omfatter en virksom mængde af forbindelsen eller et farmaceutisk acceptabelt derivat af forbindelsen ifølge et hvilket som helst af krav 1 til 22 og en farmaceutisk acceptabel bærer eller excipient.
  23. 24. In vitro fremgangsmåde til modulering af ORL-1 receptorfunktion i en celle, omfattende, at man kontakter en celle, der er i stand til at eksprimere OPL-1-receptoren, med en virksom mængde af forbindelsen eller et farmaceutisk acceptabelt derivat af forbindelsen ifølge et hvilket som helst af krav 1 til 22, hvor det farmaceutisk acceptable derivat er udvalgt fra gruppen bestående af farmaceutisk acceptabelt salt, solvat, radiomærket, stereoisomer, enantiomer, diastereomer, racemisk blanding og tautomer.
  24. 25. In vitro fremgangsmåde ifølge krav 24, hvor forbindelsen eller det farmaceutisk acceptable derivat af forbindelsen virker som en agonist på ORL-1 -receptoren, som partiel agonist pa ORL-1-receptoren eller som en antagonist på ORL-1-receptoren, hvor det farmaceutisk acceptable derivat er udvalgt fra gruppen bestående af farmaceutisk acceptabelt salt, solvat, radiomærket, stereoisomer, enantiomer, diastereomer, racemisk blanding og tautomer.
  25. 26. Kit, der omfatter en beholder, der indeholder en virksom mængde af forbindelsen eller et farmaceutisk acceptabelt derivat af forbindelsen ifølge et hvilket som helst af krav 1 til 22.
  26. 27. Fremgangsmåde til fremstilling af en sammensætning, omfattende trinnet med tilblanding af en forbindelse eller et farmaceutisk acceptabelt derivat af forbindelsen ifølge et hvilket som helst af krav 1 til 22 og en farmaceutisk acceptabel bærer eller excipiens.
  27. 28. Anvendelse af en forbindelse ifølge et hvilket som helst af krav 1 til 22 til fremstilling af et medicament, der er anvendeligt til behandling af smerte, en hukommelsesforstyrrelse, obesitet, konstipation, depression, demens, Par-kinsonisme, angst, hoste, diare, højt blodtryk, eiplepsi, anorexi/cachexi, uri-nurinary inkontinens eller stofmisbrug.
  28. 29. Forbindelse ifølge et hvilket som helst af krav 1 til 22 til anvendelse til behandling af smerte, en hukommelsesforstyrrelse, obesitet, konstipation, depression, demens, Parkinsonisme, angst, hoste, diare, højt biodtryk, eip-lepsi, anorexi/cachexi, urinurinary inkontinens eller stofmisbrug.
DK09786064T 2008-07-21 2009-07-20 Broforbundne piperidinforbindelser af substitueret quinoxalintype og anvendelser deraf DK2324013T6 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8248208P 2008-07-21 2008-07-21
PCT/IB2009/006356 WO2010010458A1 (en) 2008-07-21 2009-07-20 Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof

Publications (2)

Publication Number Publication Date
DK2324013T3 DK2324013T3 (da) 2012-11-19
DK2324013T6 true DK2324013T6 (da) 2014-12-15

Family

ID=41077776

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09786064T DK2324013T6 (da) 2008-07-21 2009-07-20 Broforbundne piperidinforbindelser af substitueret quinoxalintype og anvendelser deraf

Country Status (32)

Country Link
US (6) US8476271B2 (da)
EP (2) EP2537844A1 (da)
JP (1) JP5416210B2 (da)
KR (1) KR101333660B1 (da)
CN (1) CN102105465B (da)
AR (1) AR072578A1 (da)
AU (1) AU2009275218C1 (da)
BR (1) BRPI0911031B8 (da)
CA (1) CA2730288C (da)
CL (1) CL2011000148A1 (da)
CO (1) CO6341627A2 (da)
CY (1) CY1113485T1 (da)
DK (1) DK2324013T6 (da)
ES (1) ES2393849T7 (da)
HK (1) HK1157763A1 (da)
HR (1) HRP20120841T4 (da)
IL (2) IL210549A (da)
MX (1) MX2011000872A (da)
MY (1) MY153948A (da)
NZ (1) NZ590416A (da)
PE (2) PE20140102A1 (da)
PL (1) PL2324013T6 (da)
PT (1) PT2324013E (da)
RS (1) RS52590B2 (da)
RU (1) RU2500678C2 (da)
SG (1) SG192539A1 (da)
SI (1) SI2324013T1 (da)
SM (1) SMT201200053B (da)
TW (2) TW201016697A (da)
UA (1) UA99540C2 (da)
WO (1) WO2010010458A1 (da)
ZA (1) ZA201100189B (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2833209C (en) 2007-04-27 2016-06-28 Purdue Pharma L.P. Piperidine and piperazine compounds as trpv1 antagonists
BRPI0815327A2 (pt) 2007-08-31 2015-12-15 Purdue Pharma Lp "compostos de piperidina do tipo quinoxalina substituída e os usos destes"
RU2500678C2 (ru) 2008-07-21 2013-12-10 Пэдью Фарма Л.П. Замещенные хиноксалинового типа мостиковые пиперидиновые соединения и их применение
JP5872585B2 (ja) * 2010-12-22 2016-03-01 パーデュー、ファーマ、リミテッド、パートナーシップ リン置換キノキサリンタイプピペリジン化合物とその使用
AR086709A1 (es) 2011-06-22 2014-01-15 Purdue Pharma Lp Antagonistas trpv1 que incluyen sustituyentes dihidroxi y sus usos
US9394293B2 (en) 2011-08-10 2016-07-19 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9290488B2 (en) 2011-12-01 2016-03-22 Purdue Pharma L.P. Azetidine-substituted quinoxalines as opioid receptor like-1 modulators
US9085561B2 (en) 2012-07-30 2015-07-21 Purdue Pharma L.P. Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators
US9963458B2 (en) 2012-12-27 2018-05-08 Purdue Pharma L.P. Indole and indoline-type piperidine compounds and uses thereof
US9090618B2 (en) 2012-12-27 2015-07-28 Purdue Pharma L.P. Substituted benzimidazole-type piperidine compounds and uses thereof
WO2014102590A1 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Substituted piperidin-4-amino-type compounds and uses thereof
US9040533B2 (en) 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
JOP20190008A1 (ar) * 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
WO2019145850A1 (en) 2018-01-24 2019-08-01 Purdue Pharma L. P. Sleep disorder treatment and prevention
EP3917621A1 (en) * 2019-01-31 2021-12-08 Purdue Pharma LP Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
IL308315A (en) * 2021-05-21 2024-01-01 Purdue Pharma Lp Treatment methods for cystitis/bladder pain syndrome
WO2023250190A1 (en) * 2022-06-24 2023-12-28 Purdue Pharma L.P. Methods of treating or preventing overactive bladder syndrome

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5225402A (en) * 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US20020061554A1 (en) * 1992-08-13 2002-05-23 Evans Christopher J. Orphan opioid receptor and recombinant materials for its production
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
ATE216580T1 (de) 1993-07-16 2002-05-15 Merck & Co Inc Benzoxazinon- und benzopyrimidinon- piperidinyl- verbindungen als tokolytische oxytocin-rezeptor- antagonisten
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE69635048T2 (de) 1995-06-12 2006-02-16 G.D. Searle & Co. Mittel, enthaltend einen cyclooxygenase-2 inhibitor und einen 5-lipoxygenase inhibitor
JP3776201B2 (ja) 1997-04-17 2006-05-17 株式会社リコー 光記録媒体
KR20010020172A (ko) 1997-05-30 2001-03-15 나가사까 겐지로 2-옥소이미다졸 유도체
KR100588247B1 (ko) 1997-09-01 2006-06-13 교린 세이야꾸 가부시키 가이샤 6,7-비대칭 이치환된 퀴녹살린카복실산 유도체와 이의부가염 및 이들의 제조방법
SE9800836D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
WO1999051582A1 (fr) * 1998-03-31 1999-10-14 Kyowa Hakko Kogyo Co., Ltd. Composes heterocycliques azotes
HUP0101470A3 (en) 1998-03-31 2002-09-30 Warner Lambert Co Quinoxalinones as serine protease inhibitors such as factor xa and thrombin and medicaments containing the compounds
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
MA26659A1 (fr) 1998-08-06 2004-12-20 Pfizer Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DE60022226D1 (de) 1999-12-06 2005-09-29 Euro Celtique Sa Benzimidazolverbindungen die nociceptinrezeptoraffinität haben
JP3989247B2 (ja) 1999-12-06 2007-10-10 ユーロ−セルティーク エス．エイ． ノシセプチン受容体親和性を有するトリアゾスピロ化合物
WO2001090102A2 (de) 2000-05-24 2001-11-29 Bayer Aktiengesellschaft 6-heterocyclyl-3-oxo-3,4-dihydro-chinoxaline
US6867222B2 (en) 2001-04-18 2005-03-15 Euro-Celtique, S.A. Nociceptin analogs
KR100855204B1 (ko) 2001-04-18 2008-09-01 유로-셀티크 소시에떼 아노뉨 노시셉틴 유사체
ATE403429T1 (de) 2001-04-18 2008-08-15 Euro Celtique Sa Spiropyrazol-verbindungen
WO2002085354A1 (en) 2001-04-18 2002-10-31 Euro-Celtique S.A. Spiroindene and spiroindane compounds
ES2312616T3 (es) 2001-04-18 2009-03-01 Euro-Celtique S.A. Compuestos de bencimidazolona.
EP1382598A4 (en) * 2001-04-26 2005-03-23 Takeda Pharmaceutical NEW HETEROCYCLIC DERIVATIVES
DE10123163A1 (de) * 2001-05-09 2003-01-16 Gruenenthal Gmbh Substituierte Cyclohexan-1,4-diaminderivate
EP1396488A1 (en) * 2001-05-23 2004-03-10 Mitsubishi Pharma Corporation Fused heterocyclic compound and medicinal use thereof
TWI317360B (en) * 2001-11-07 2009-11-21 Schering Corp Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
WO2003062234A1 (fr) 2002-01-23 2003-07-31 Yamanouchi Pharmaceutical Co., Ltd. Composes de quinoxaline
US7026312B2 (en) * 2002-03-14 2006-04-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
US7566728B2 (en) * 2002-03-29 2009-07-28 Mitsubishi Tanabe Pharma Corporation Remedy for sleep disturbance
MXPA05003881A (es) 2002-10-17 2005-10-05 Euro Celtique Sa Preparacion de compuestos triazospiro.
DE10343098A1 (de) 2003-09-18 2005-04-14 Bayer Healthcare Ag Tetrahydrochinoxaline und ihre Verwendung
AR045939A1 (es) * 2003-09-25 2005-11-16 Solvay Pharm Bv Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos
WO2005060947A2 (en) * 2003-12-19 2005-07-07 Sri International Agonist and antagonist ligands of the nociceptin receptor
DE10360793A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP1711484A4 (en) 2004-02-03 2007-06-20 Euro Celtique Sa SYNTHESIS OF CYANOIMINO-BENZOIMIDAZOLES
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
EP1676843A1 (en) * 2004-12-31 2006-07-05 Nikem Research S.R.L. Substituted indole ligands for the ORL-1 receptor
EP1893610A2 (en) * 2005-06-17 2008-03-05 Pfizer, Inc. Alpha-(aryl-or heteroaryl-methyl)-beta piperidino propanamide compounds as orl1-receptor antagonists
US7300947B2 (en) * 2005-07-13 2007-11-27 Banyu Pharmaceutical Co., Ltd. N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives
PE20071159A1 (es) * 2005-10-31 2007-11-30 Schering Corp Derivados de tropano 3-monosustituido como ligandos de receptores de nociceptina
TW200815405A (en) 2006-06-09 2008-04-01 Astrazeneca Ab Novel compounds
EP1873150A1 (en) 2006-06-30 2008-01-02 Nikem Research S.R.L. Fluorinated indoleamides useful as ligands of the ORL-1 receptor
RS51474B (en) * 2007-01-16 2011-04-30 Purdue Pharma L.P. HETEROCYCLICALLY SUBSTITUTED PIPERIDINES AS ORL-1 LIGANDS
JP5313865B2 (ja) * 2007-03-01 2013-10-09 田辺三菱製薬株式会社 ベンゾイミダゾール化合物およびその医薬用途
BRPI0815327A2 (pt) * 2007-08-31 2015-12-15 Purdue Pharma Lp "compostos de piperidina do tipo quinoxalina substituída e os usos destes"
US8815876B2 (en) * 2008-07-16 2014-08-26 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
RU2500678C2 (ru) * 2008-07-21 2013-12-10 Пэдью Фарма Л.П. Замещенные хиноксалинового типа мостиковые пиперидиновые соединения и их применение

Also Published As

Publication number Publication date
US20130274265A1 (en) 2013-10-17
RS52590B (en) 2013-04-30
WO2010010458A1 (en) 2010-01-28
SG192539A1 (en) 2013-08-30
RU2500678C2 (ru) 2013-12-10
US20180148449A1 (en) 2018-05-31
CO6341627A2 (es) 2011-11-21
NZ590416A (en) 2012-10-26
US20160009717A1 (en) 2016-01-14
SI2324013T1 (sl) 2012-12-31
CL2011000148A1 (es) 2011-09-02
PT2324013E (pt) 2012-12-24
JP5416210B2 (ja) 2014-02-12
RU2011106375A (ru) 2012-08-27
US8476271B2 (en) 2013-07-02
PE20140102A1 (es) 2014-02-06
EP2324013B1 (en) 2012-09-19
TW201016697A (en) 2010-05-01
ES2393849T3 (es) 2012-12-28
AU2009275218B2 (en) 2012-11-08
US10519156B2 (en) 2019-12-31
US20180370971A1 (en) 2018-12-27
HRP20120841T1 (hr) 2012-11-30
IL254218A0 (en) 2017-10-31
AR072578A1 (es) 2010-09-08
BRPI0911031B1 (pt) 2021-05-11
US9890164B2 (en) 2018-02-13
PE20110416A1 (es) 2011-06-22
CN102105465A (zh) 2011-06-22
CA2730288C (en) 2016-09-13
EP2537844A1 (en) 2012-12-26
IL210549A (en) 2017-09-28
KR101333660B1 (ko) 2013-11-27
ZA201100189B (en) 2011-09-28
EP2324013A1 (en) 2011-05-25
IL210549A0 (en) 2011-03-31
PL2324013T3 (pl) 2013-05-31
KR20110031993A (ko) 2011-03-29
BRPI0911031B8 (pt) 2021-05-25
US20110178090A1 (en) 2011-07-21
SMT201200053B (it) 2013-01-14
BRPI0911031A2 (pt) 2017-01-17
AU2009275218C1 (en) 2015-02-05
US9145408B2 (en) 2015-09-29
CA2730288A1 (en) 2010-01-28
MX2011000872A (es) 2011-07-29
TWI432434B (zh) 2014-04-01
US11111246B2 (en) 2021-09-07
HRP20120841T4 (hr) 2015-07-03
JP2011528707A (ja) 2011-11-24
AU2009275218A1 (en) 2010-01-28
RS52590B2 (sr) 2018-05-31
CY1113485T1 (el) 2016-06-22
DK2324013T3 (da) 2012-11-19
TW201329077A (zh) 2013-07-16
CN102105465B (zh) 2015-03-11
US20200223847A1 (en) 2020-07-16
ES2393849T7 (es) 2015-01-28
EP2324013B3 (en) 2014-10-22
HK1157763A1 (en) 2012-07-06
MY153948A (en) 2015-04-15
UA99540C2 (ru) 2012-08-27
PL2324013T6 (pl) 2015-11-30

Similar Documents

Publication Publication Date Title
US11111246B2 (en) Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds
US9527840B2 (en) Substituted-quinoxaline-type piperidine compounds and the uses thereof
US8110602B2 (en) Compounds comprising heterocyclic-substituted piperidine for treating pain
US9598447B2 (en) Phosphorus-substituted quinoxaline-type piperidine compounds and uses thereof
WO2014102590A1 (en) Substituted piperidin-4-amino-type compounds and uses thereof
WO2014102589A1 (en) Quinazolin-4(3h)-one-type piperidine compounds and uses thereof
AU2012261662A1 (en) Substituted-quinoxaline-type bridged-piperidine compounds and the uses thereof